Professional Media briefs: BMJ, Docphin, Quadrant HealthCom and BMJ.com

Share this article:

Occurrence of articles with honorary or ghost authorship is down, but more than one of five papers in high-impact journals has signs of inappropriate authorship, researchers wrote in BMJ. They called for more measures by journals, authors and academic institutions “to prevent a practice that might lead to loss of public confidence.”

Two MDs and an IMS Consulting Group alum started Docphin, a free web service designed to help physicians find and personalize medical news and research from journals and news sources—all from a single dashboard.

Quadrant HealthCom named Christy Tetterton and Hillary Ford group publishers. Tetterton joined the firm a year ago to manage The Journal of Family Practice and Mayo Clinic Proceedings. Ford joins the company as group publisher of the CNS division, coming from Direct Medical Data, where she was practice leader for medical publishing.

BMJ.com saw its first redesign since 2007. Among changes are navigational tabs for articles, social networking links and a free resource to help users track and record CME credits. BMJ continues to be an open access journal.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?